减毒活霍乱疫苗菌株CVD 103-HgR在O血型人群中引发的血清杀弧菌抗体滴度显著更高。
Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
作者信息
Lagos R, Avendaño A, Prado V, Horwitz I, Wasserman S, Losonsky G, Cryz S, Kaper J B, Levine M M
机构信息
Centro para Vacunas en Desarrollo-Chile.
出版信息
Infect Immun. 1995 Feb;63(2):707-9. doi: 10.1128/iai.63.2.707-709.1995.
Abstract
Persons of blood group O are at increased risk of developing cholera gravis. In a randomized, placebo-controlled, double-blind safety-immunogenicity trial of live oral cholera vaccine CVD 103-HgR in 5- to 9-year-old Chilean children, vibriocidal antibody seroconversion (74% overall) did not differ by blood group. However, the reciprocal geometric mean titer (GMT) in blood group O vaccines (GMT = 486) was higher than that in non-O vaccines (GMT = 179) (P < 0.02).
摘要
O型血的人患重症霍乱的风险更高。在一项针对5至9岁智利儿童的口服霍乱活疫苗CVD 103-HgR的随机、安慰剂对照、双盲安全性-免疫原性试验中，杀菌抗体血清转化率（总体为74%）在不同血型之间没有差异。然而，O型血疫苗接种者的几何平均滴度倒数（GMT = 486）高于非O型血疫苗接种者（GMT = 179）（P < 0.02）。
相似文献
1
Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O.
Infect Immun. 1995 Feb;63(2):707-9. doi: 10.1128/iai.63.2.707-709.1995.
2
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00265-17. Print 2017 Dec.
3
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
Bull World Health Organ. 1998;76(1):63-71.
4
[Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Rev Med Chil. 1993 Aug;121(8):857-63.
5
Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children.
Lancet. 1992 Sep 19;340(8821):689-94. doi: 10.1016/0140-6736(92)92231-4.
6
Palatability, reactogenicity and immunogenicity of engineered live oral cholera vaccine CVD 103-HgR in Chilean infants and toddlers.
Pediatr Infect Dis J. 1999 Jul;18(7):624-30. doi: 10.1097/00006454-199907000-00011.
7
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
Infect Immun. 1997 Sep;65(9):3852-6. doi: 10.1128/iai.65.9.3852-3856.1997.
8
PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348.
9
Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
Infect Immun. 1989 Nov;57(11):3261-4. doi: 10.1128/iai.57.11.3261-3264.1989.
10
Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Bull Pan Am Health Organ. 1995 Dec;29(4):312-21.
引用本文的文献
1
Geographic disparities impacting oral vaccine performance: Observations and future directions.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae124.
2
Variations in the Antivirulence Effects of Fatty Acids and Virstatin against Strains.
J Microbiol Biotechnol. 2024 Sep 28;34(9):1757-1768. doi: 10.4014/jmb.2405.05002. Epub 2024 Jul 19.
3
Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6-17 Years.
Am J Trop Med Hyg. 2020 Jan;102(1):48-57. doi: 10.4269/ajtmh.19-0241.
4
Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba.
PLoS Negl Trop Dis. 2019 Nov 19;13(11):e0007874. doi: 10.1371/journal.pntd.0007874. eCollection 2019 Nov.
5
Factors That Influence the Immune Response to Vaccination.
Clin Microbiol Rev. 2019 Mar 13;32(2). doi: 10.1128/CMR.00084-18. Print 2019 Mar 20.
6
Causes of impaired oral vaccine efficacy in developing countries.
Future Microbiol. 2018 Jan;13(1):97-118. doi: 10.2217/fmb-2017-0128. Epub 2017 Dec 8.
7
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator.
Clin Vaccine Immunol. 2017 Dec 5;24(12). doi: 10.1128/CVI.00265-17. Print 2017 Dec.
8
Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.
Hum Vaccin Immunother. 2014;10(6):1457-65. doi: 10.4161/hv.29199. Epub 2014 May 26.
9
Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.
PLoS Negl Trop Dis. 2014 May 1;8(5):e2828. doi: 10.1371/journal.pntd.0002828. eCollection 2014 May.
10
Age-dependent association among Helicobacter pylori infection, serum pepsinogen levels and immune response of children to live oral cholera vaccine CVD 103-HgR.
PLoS One. 2014 Jan 15;9(1):e83999. doi: 10.1371/journal.pone.0083999. eCollection 2014.
本文引用的文献
1
Live oral vaccines against cholera: an update.
Vaccine. 1993;11(2):207-12. doi: 10.1016/0264-410x(93)90019-t.
2
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
Infect Immun. 1993 Sep;61(9):3994-7. doi: 10.1128/iai.61.9.3994-3997.1993.
3
[Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Rev Med Chil. 1993 Aug;121(8):857-63.
4
Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children.
J Infect Dis. 1993 Nov;168(5):1169-76. doi: 10.1093/infdis/168.5.1169.
5
Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens.
Science. 1993 Dec 17;262(5141):1892-5. doi: 10.1126/science.8018146.
6
[Assessment and standardization of the body mass index in French males aged 18-59 years].
C R Acad Sci III. 1995 Jun;318(6):709-14.
7
Duration of infection-derived immunity to cholera.
J Infect Dis. 1981 Jun;143(6):818-20. doi: 10.1093/infdis/143.6.818.
8
Endemic cholera in rural Bangladesh, 1966-1980.
Am J Epidemiol. 1982 Dec;116(6):959-70. doi: 10.1093/oxfordjournals.aje.a113498.
9
Characterization and distribution of the hemagglutinins produced by Vibrio cholerae.
Infect Immun. 1982 Apr;36(1):209-14. doi: 10.1128/iai.36.1.209-214.1982.
10
Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.
Bull World Health Organ. 1968;38(2):277-85.
Zotero 插件